ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer

References

• Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg. 2016;49(5):1324–14. doi:10.1093/ejcts/ezv371.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482. doi:10.1038/nrclinonc.2017.43.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–1680. doi:10.1056/NEJM198812223192527.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730. doi:10.1038/s41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(Suppl 2):S87–97. doi:10.3747/co.27.5223.
   PubMed Web of Science ®Google Scholar
• O’donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167. doi:10.1038/s41571-018-0142-8.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–461. doi:10.1007/s00428-018-2484-0.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. doi:10.1038/ni1582.
   PubMed Web of Science ®Google Scholar
• Torres Cepeda TE, Alanis Guzman MG, Maiti R. Relationship between nutritional composition and anatomical parameters in sorghum (Sorghum bicolor L. Moench). Arch Latinoam Nutr. 1996;46:253–259.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799. doi:10.1016/S0140-6736(00)03231-1.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1.
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32(2):135–154. doi:10.1016/j.ccell.2017.06.009.
   PubMed Web of Science ®Google Scholar
• Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835–847. doi:10.1038/s41590-020-0728-z.
   PubMed Web of Science ®Google Scholar
• Li Y, Yin J, Li T, Huang S, Yan H, Leavenworth J, Wang X. NK cell-based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci. 2015;58(12):1233–1245. doi:10.1007/s11427-015-4970-9.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the Tumor Microenvironment on NK cell function in solid Tumors. Front Immunol. 2019;10:3038. doi:10.3389/fimmu.2019.03038.
   Google Scholar
• Habif G, Crinier A, Andre P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415–422. doi:10.1038/s41423-019-0224-2.
   PubMed Web of Science ®Google Scholar
• Cozar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11(1):34–44. doi:10.1158/2159-8290.CD-20-0655.
   PubMed Web of Science ®Google Scholar
• Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014;5(1):5639. doi:10.1038/ncomms6639.
   PubMedGoogle Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3499–3510. doi:10.1158/0008-5472.CAN-13-0371.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131. doi:10.1158/2326-6066.CIR-14-0160.
   PubMed Web of Science ®Google Scholar
• Bule P, Aguiar SI, Aires-Da-Silva F, Dias JNR. Chemokine-directed Tumor microenvironment Modulation in Cancer Immunotherapy. Int J Mol Sci. 2021;22(18):9804. doi:10.3390/ijms22189804.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ren Y, Xie H, Yu L, Lu J, Jiang W, Xiao W, Zhu Z, Wan R, Li B. ELK3 mediated by ZEB1 facilitates the growth and metastasis of Pancreatic carcinoma by activating the Wnt/β-catenin pathway. Front Cell Dev Biol. 2021;9:700192. doi:10.3389/fcell.2021.700192.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ren Z, Zhang C, Qian R, Wang H, Wang J, Zhang W, Liu B, Lian X, Wang Y, et al. ELK3: a new molecular marker for the diagnosis and Prognosis of Glioma. Front Oncol. 2021;11:608748. doi:10.3389/fonc.2021.608748.
   PubMed Web of Science ®Google Scholar
• Kim KS, Park JI, Oh N, Cho HJ, Park JH, Park KS. ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRnas. Sci Rep. 2019;9(1):8418. doi:10.1038/s41598-019-44828-6.
   PubMedGoogle Scholar
• Cho HJ, Oh N, Park JH, Kim KS, Kim HK, Lee E, Hwang S, Kim S-J, Park K-S. ZEB1 Collaborates with ELK3 to repress E-Cadherin expression in Triple-negative breast cancer cells. Mol Cancer Res. 2019;17(11):2257–2266. doi:10.1158/1541-7786.MCR-19-0380.
   PubMed Web of Science ®Google Scholar
• Park JD, Kim KS, Choi SH, Jo GH, Choi JH, Park SW, Ko E-S, Lee M, Lee D-K, Jang HJ, et al. ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. J ImmunoTher Cancer. 2022;10(7):e004825. doi:10.1136/jitc-2022-004825.
   PubMed Web of Science ®Google Scholar
• Kim HK, Park JD, Choi SH, Shin DJ, Hwang S, Jung HY, Park K-S. Functional link between miR-200a and ELK3 regulates the metastatic nature of breast cancer. Cancers (Basel). 2020;12(5):1225. doi:10.3390/cancers12051225.
   PubMed Web of Science ®Google Scholar
• Lee M, Cho HJ, Park KS, Jung HY. ELK3 controls Gastric cancer cell migration and invasion by regulating ECM remodeling-related genes. Int J Mol Sci. 2022;23(7):3709. doi:10.3390/ijms23073709.
   PubMed Web of Science ®Google Scholar
• Oh N, Park JI, Park JH, Kim KS, Lee DR, Park KS. The role of ELK3 to regulate peritumoral lymphangiogenesis and VEGF-C production in triple negative breast cancer cells. Biochem Biophys Res Commun. 2017;484(4):896–902. doi:10.1016/j.bbrc.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Zhuo W, Jia L, Song N, Lu XA, Ding Y, Wang X, Song X, Fu Y, Luo Y. The CXCL12–CXCR4 Chemokine Pathway: a novel axis regulates Lymphangiogenesis. Clin Cancer Res. 2012;18(19):5387–5398. doi:10.1158/1078-0432.CCR-12-0708.
   PubMed Web of Science ®Google Scholar
• Tsoyi K, Geldart AM, Christou H, Liu X, Chung SW, Perrella MA. Elk-3 is a KLF4-regulated gene that modulates the phagocytosis of bacteria by macrophages. J Leukoc Biol. 2015;97(1):171–180. doi:10.1189/jlb.4A0214-087R.
   PubMed Web of Science ®Google Scholar
• Dazhi W, Zheng J, Chunling R. High ELK3 expression is associated with the VEGF-C/VEGFR-3 axis and gastric tumorigenesis and enhances infiltration of M2 macrophages. Future Med Chem. 2020;12(24):2209–2224. doi:10.4155/fmc-2019-0337.
   PubMed Web of Science ®Google Scholar
• Choi YH, Lim EJ, Kim SW, Moon YW, Park KS, An HJ. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells. J ImmunoTher Cancer. 2019;7(1):168. doi:10.1186/s40425-019-0652-7.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Jung HY, Fattet L, Tsai JH, Kajimoto T, Chang Q, Newton AC, Yang J. Apical–basal polarity inhibits epithelial–mesenchymal transition and tumour metastasis by PAR-complex-mediated SNAI1 degradation. Nat Cell Biol. 2019;21(3):359–371. doi:10.1038/s41556-019-0291-8.
   PubMed Web of Science ®Google Scholar
• Kong SY, Kim KS, Kim J, Kim MK, Lee KH, Lee JY, Oh N, Park J-I, Park J-H, Heo S-H, et al. The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo. Oncotarget. 2016;7(40):65137–65146. doi:10.18632/oncotarget.11427.
   PubMedGoogle Scholar
• Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. Tcgabiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. doi:10.1093/nar/gkv1507.
   PubMed Web of Science ®Google Scholar
• Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, Behren A, Huntington ND, Davis MJ. A Gene signature predicting natural killer cell infiltration and improved Survival in Melanoma patients. Cancer Immunol Res. 2019;7(7):1162–1174. doi:10.1158/2326-6066.CIR-18-0500.
   PubMed Web of Science ®Google Scholar
• Grundemann C, Bauer M, Schweier O, von Oppen N, Lassing U, Saudan P, Becker K-F, Karp K, Hanke T, Bachmann MF, et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol. 2006;176(3):1311–1315. doi:10.4049/jimmunol.176.3.1311.
   PubMed Web of Science ®Google Scholar
• Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest. 2018;128(4):1384–1396. doi:10.1172/JCI97611.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167–2176. doi:10.1182/blood-2009-08-238469.
   PubMed Web of Science ®Google Scholar
• Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol. 2010;341:37–58.
   PubMed Web of Science ®Google Scholar
• Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10–21. doi:10.1038/s41417-021-00303-x.
   PubMed Web of Science ®Google Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3–15. doi:10.1007/s12282-016-0698-z.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036. doi:10.1038/ni.3518.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68(20):8437–8445. doi:10.1158/0008-5472.CAN-08-1440.
   PubMed Web of Science ®Google Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6(1):7458. doi:10.1038/ncomms8458.
   PubMed Web of Science ®Google Scholar
• Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, et al. Mobilization of CD8(+) T cells via CXCR4 Blockade Facilitates PD-1 Checkpoint therapy in human Pancreatic cancer. Clin Cancer Res. 2019;25(13):3934–3945. doi:10.1158/1078-0432.CCR-19-0081.
   PubMed Web of Science ®Google Scholar
• Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099–3107. doi:10.4049/jimmunol.181.5.3099.
   PubMed Web of Science ®Google Scholar
• Yoon MS, Pham CT, Phan MT, Shin DJ, Jang YY, Park MH, Kim S-K, Kim S, Cho D. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. Cytotherapy. 2016;18(12):1532–1542. doi:10.1016/j.jcyt.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Yang H, Schramek D, Adam R C, Keyes B E, Wang P, Zheng D, Fuchs E. ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. Elife. 2015;4:e10870. doi:10.7554/eLife.10870.
   PubMed Web of Science ®Google Scholar